Lipum AB (LIPUM) - Total Assets
Based on the latest financial reports, Lipum AB (LIPUM) holds total assets worth Skr6.88 Million SEK (≈ $740.94K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Lipum AB net asset quality index to measure how much of total assets are equity-financed.
Lipum AB - Total Assets Trend (2017–2025)
This chart illustrates how Lipum AB's total assets have evolved over time, based on quarterly financial data. Check LIPUM cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Lipum AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Lipum AB's total assets of Skr6.88 Million consist of 98.6% current assets and 1.4% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 22.6% |
| Accounts Receivable | Skr1.49 Million | 21.7% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Lipum AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Lipum AB market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lipum AB's current assets represent 98.6% of total assets in 2025, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 22.6% of total assets in 2025, down from 92.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 21.7% of total assets.
Lipum AB Competitors by Total Assets
Key competitors of Lipum AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Lipum AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.58 | 2.10 | 0.78 |
| Quick Ratio | 0.58 | 2.10 | 0.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr-4.84 Million | Skr23.72 Million | Skr-1.41 Million |
Lipum AB - Advanced Valuation Insights
This section examines the relationship between Lipum AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.19 |
| Latest Market Cap to Assets Ratio | 4.76 |
| Asset Growth Rate (YoY) | -84.9% |
| Total Assets | Skr6.88 Million |
| Market Capitalization | $32.76 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Lipum AB's assets at a significant premium (4.76x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Lipum AB's assets decreased by 84.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lipum AB (2017–2025)
The table below shows the annual total assets of Lipum AB from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr6.88 Million ≈ $740.94K |
-84.87% |
| 2024-12-31 | Skr45.51 Million ≈ $4.90 Million |
+275.79% |
| 2023-12-31 | Skr12.11 Million ≈ $1.30 Million |
-64.95% |
| 2022-12-31 | Skr34.55 Million ≈ $3.72 Million |
-30.43% |
| 2021-12-31 | Skr49.66 Million ≈ $5.34 Million |
+392.27% |
| 2020-12-31 | Skr10.09 Million ≈ $1.09 Million |
-42.50% |
| 2019-12-31 | Skr17.54 Million ≈ $1.89 Million |
+91.81% |
| 2018-12-31 | Skr9.15 Million ≈ $984.33K |
+204.86% |
| 2017-12-31 | Skr3.00 Million ≈ $322.88K |
-- |
About Lipum AB
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. The company develops SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. It has a collaboration with NorthXBiologies for production of SOL-116 setatt; and a… Read more